Integra Lifesciences Holdings Corp

IART

9.200USD

-0.180-1.92%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Integra Lifesciences Holdings Corp's Score

Industry at a Glance

Industry Ranking

76 / 208

Overall Ranking

196 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Integra Lifesciences Holdings Corp Highlights

StrengthsRisks

Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. It provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.

Fairly Valued

The company’s latest PE is -1.37, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.73M shares, decreasing 25.06% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 341.46K shares of this stock.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

16.333

Target Price

+74.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Integra Lifesciences Holdings Corp is 6.16, ranking 166 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 434.93M, representing a year-over-year decrease of 1.74%, while its net profit experienced a year-over-year decrease of 108.77%.

Score

Industry at a Glance

Previous score

6.16

Change

0



Financials

5.15

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.19

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.57

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.33

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Integra Lifesciences Holdings Corp is 8.05, ranking 47 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.37, which is -7985.42% below the recent high of 107.70 and -21991.74% above the recent low of -301.73.

Score

Industry at a Glance

Previous score

8.05

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/208

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Integra Lifesciences Holdings Corp is 6.00, ranking 175 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 13.00, with a high of 25.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

6.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Integra Lifesciences Holdings Corp is 6.51, ranking 117 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 10.64 and the support level at 8.23, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

-0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Integra Lifesciences Holdings Corp is 10.00, ranking 1 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 95.94%, representing a quarter-over-quarter increase of 1.60%. The largest institutional shareholder is The Vanguard, holding a total of 7.12M shares, representing 9.13% of shares outstanding, with 5.03% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

9.29M

-1.55%

TRU ST Partnership, L.P.

8.52M

--

Rubric Capital Management LP

7.65M

+4.08%

The Vanguard Group, Inc.

Star Investors

7.29M

-2.89%

Fuller & Thaler Asset Management Inc.

3.91M

+0.56%

Invesco Advisers, Inc.

3.18M

+0.10%

Dimensional Fund Advisors, L.P.

3.18M

+9.16%

State Street Investment Management (US)

2.79M

-1.26%

Boston Management and Research

2.74M

--

Paradigm Capital Management, Inc.

2.53M

+15.97%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Integra Lifesciences Holdings Corp is 4.82, ranking 96 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.08. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Integra Lifesciences Holdings Corp’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Integra Lifesciences Holdings Corp

IART

6.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bioventus Inc

BVS

8.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.13 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Edwards Lifesciences Corp

EW

8.05 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment